Skip to main content
Premium Trial:

Request an Annual Quote

CuraGen, Mitsubishi Pharma do Schizophrenia Drug Deal

NEW YORK, Nov. 5-CuraGen will use its functional genomics techniques to validate and characterize drug targets for schizophrenia for Mitsubishi Pharma Corporation, the two companies said today.


CuraGen will retain ownership of new protein therapeutics, antibody drugs and small molecule targets discovered in this partnership. MPC will also provide the company with undisclosed financial support.


SC Biosciences, CuraGen's Japanese agent, helped execute this deal.


For more information, see the press release.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.